Close Menu

pachyonychia congenita

TransDerm, a small biotech focused on developing a treatment for pachyonychia congenita (PC), has just kicked off a phase I trial of a new drug candidate designed to treat the rare skin condition.

TransDerm is preparing to begin the toxicology studies needed to launch a phase I trial of an improved version of its siRNA-based treatment for pachyonychia congenita, or PC, and expects the study to begin next year, Gene Silencing News has learned.

TransDerm, a small firm developing RNAi-based treatments for rare skin disorders, said this week that it has been awarded a $4 million grant from the National Institutes of Health to develop a technology for siRNA delivery into the skin.

In addition to evaluating RXi's proprietary RNAi compounds, TransDerm will test delivery technologies from Traversa Therapeutics, Thermo Fisher Scientific, and Life Technologies.

Additional clinical trials will likely use an experimental topical delivery vehicle after intradermal injections proved more painful to the patient than expected.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.